Eleanor de Groot
Chief Tech/Sci/R&D Officer presso BRII BIOSCIENCES LIMITED
Profilo
Eleanor M.
de Groot is currently the Chief Technology Officer at Brii Biosciences Ltd.
(China).
Prior to this, she was the Executive Vice President-Operations at Alaunos Therapeutics, Inc. from 2015 to 2022 and the Vice President-Technical Operations at Helsinn Therapeutics (U.S.), Inc. from 2009 to 2015.
She also held positions as Principal at Guilford Pharmaceuticals, Inc. and Shell Chemicals Ltd., and as Vice President-Technical Operations at Sapphire Therapeutics, Inc. Dr. de Groot holds a doctorate degree from Stanford University, a graduate degree from Stanford University, an MBA from Rice University, and an undergraduate degree from Massachusetts Institute of Technology.
Posizioni attive di Eleanor de Groot
| Società | Posizione | Inizio |
|---|---|---|
| BRII BIOSCIENCES LIMITED | Chief Tech/Sci/R&D Officer | 15/08/2022 |
Precedenti posizioni note di Eleanor de Groot
| Società | Posizione | Fine |
|---|---|---|
| ALAUNOS THERAPEUTICS, INC. | Chief Operating Officer | 01/05/2022 |
Helsinn Therapeutics (U.S.), Inc.
 Helsinn Therapeutics (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Helsinn Therapeutics (U.S.), Inc. develops, manufactures and supplies pharmaceutical products for treatment of cancer. The company is headquartered in Iselin. NJ. | Corporate Officer/Principal | 01/07/2015 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Corporate Officer/Principal | - |
Shell Chemicals Ltd.
 Shell Chemicals Ltd. Chemicals: SpecialtyProcess Industries Shell Chemicals Ltd. manufactures basic organic and inorganic chemicals. Its products include alpha olefins, aromatics, corterra, ethylene oxide, lower olefins, solvents, and propylene oxide. The company was founded in 1929 and is headquartered in London, UK. | Corporate Officer/Principal | - |
Sapphire Therapeutics, Inc.
 Sapphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sapphire Therapeutics, Inc. develops biopharmaceutical products. It develops compounds for the treatment of oncologic and metabolic diseases. The firm products include anamorelin for the treatment of anorexia and cachexia. The company was founded in 2000 and is headquartered in Bridgewater, NJ. | Chief Tech/Sci/R&D Officer | - |
Formazione di Eleanor de Groot
| Stanford University | Doctorate Degree |
| Rice University | Masters Business Admin |
| Massachusetts Institute of Technology | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ALAUNOS THERAPEUTICS, INC. | Health Technology |
| BRII BIOSCIENCES LIMITED | Commercial Services |
| Aziende private | 4 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
Sapphire Therapeutics, Inc.
Sapphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sapphire Therapeutics, Inc. develops biopharmaceutical products. It develops compounds for the treatment of oncologic and metabolic diseases. The firm products include anamorelin for the treatment of anorexia and cachexia. The company was founded in 2000 and is headquartered in Bridgewater, NJ. | Health Technology |
Shell Chemicals Ltd.
Shell Chemicals Ltd. Chemicals: SpecialtyProcess Industries Shell Chemicals Ltd. manufactures basic organic and inorganic chemicals. Its products include alpha olefins, aromatics, corterra, ethylene oxide, lower olefins, solvents, and propylene oxide. The company was founded in 1929 and is headquartered in London, UK. | Process Industries |
Helsinn Therapeutics (U.S.), Inc.
Helsinn Therapeutics (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Helsinn Therapeutics (U.S.), Inc. develops, manufactures and supplies pharmaceutical products for treatment of cancer. The company is headquartered in Iselin. NJ. | Health Technology |
- Borsa valori
- Insiders
- Eleanor de Groot
